Arrowhead (NASDAQ: ARWR) CMO granted 75,000 RSUs at $0

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals Chief Medical Officer James C. Hamilton reported an equity grant of 75,000 shares of common stock on January 6, 2026. These shares represent restricted stock units that will vest in four equal annual installments, meaning the award will be earned gradually over four years if conditions are met.

Following this grant, Hamilton beneficially owns 246,958 shares of Arrowhead common stock in total. The filing shows the grant price as $0 per share, which is typical for restricted stock units issued as part of executive compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton James C

(Last) (First) (Middle)

177 EAST COLORADO BLVD

SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		75,000(1)	A	$0	246,958(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units which will vest in four equal annual installments.

2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/James Hamilton	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ARWR report for its Chief Medical Officer?

The Chief Medical Officer, James C. Hamilton, reported receiving 75,000 shares of Arrowhead Pharmaceuticals common stock in the form of restricted stock units on January 6, 2026.

How many Arrowhead (ARWR) shares does James C. Hamilton own after this Form 4?

After the reported grant, James C. Hamilton beneficially owns 246,958 shares of Arrowhead Pharmaceuticals common stock.

What are the vesting terms of the 75,000 ARWR restricted stock units?

The 75,000 restricted stock units will vest in four equal annual installments, so the award is spread evenly over four years, subject to vesting conditions.

Did the Arrowhead CMO pay for the 75,000 shares reported on the Form 4?

No cash payment is shown; the Form 4 lists a price of $0 per share, which is typical for restricted stock units granted as part of compensation.

Are all of James C. Hamilton’s ARWR shares fully vested?

No. The filing notes that his total includes previously reported restricted stock units, and a portion of these shares is still subject to vesting conditions.

What role does James C. Hamilton hold at Arrowhead Pharmaceuticals (ARWR)?

James C. Hamilton is an officer of Arrowhead Pharmaceuticals and serves as the company’s Chief Medical Officer, according to the Form 4.